logo
Plus   Neg
Share
Email

Dr. Reddy's Laboratories Launches Fosaprepitant For Injection In U.S. Market

Pharmaceutical company Dr. Reddy's Laboratories Ltd. (RDY) announced Wednesday the launch of Fosaprepitant for Injection, the therapeutic generic equivalent of EMEND (fosaprepitant) for injection, approved by the U.S. Food and Drug Administration (USFDA). It is among the first generics to launch this product.

The EMEND for Injection brand had an U.S. sales of approximately $279 million MAT for the most recent twelve months ending in July 2019 according to IQVIA Health.

Dr. Reddy's Fosaprepitant for Injection is available in 150 mg single-dose vial for reconstitution.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the third quarter on Friday, American Express Co. (AXP) reaffirmed its earnings and revenue growth guidance for the full-year 2019. The company also provided revenue growth outlook for the fourth quarter. For fiscal 2019, the company continues to project earnings... The Coca-Cola Company (KO) reported that its third-quarter comparable earnings per share declined 2 percent year-on-year to $0.56. Comparable EPS performance included the impact from a 6-point currency headwind. On average, 20 analysts polled by Thomson Reuters expected the company to report profit per... The United Auto Workers at General Motors will remain on strike until ratification of a new four-year labor contract, the union said on Thursday. GM's proposed agreement includes an $11,000 ratification bonus to workers, wage increases of 4 percent throughout the four-year contract, no increases in health care costs; and a path to permanent worker status within four years or less.
RELATED NEWS
Follow RTT
>